Soligenix increased its at-the-market issuance capacity by $2,500,000 under the Rodman & Renshaw sales agreement.

Key Highlights:

  • Filed prospectus supplement to raise maximum aggregate offering under the Sales Agreement by $2,500,000.
  • Previous sales under the agreement totaled approximately $6,234,000 against prior capacity of $6,406,000.
  • Legal opinion covering the additional $2,500,000 of common stock is attached as Exhibit 5.1.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.